000000_Synthonics_ChyloCureBook_Rev031919

These projections assume that annual market growth is 65% through 2021 and 15% thereafter, that ChlyloCure’s market share grows at 10% per year, and that the cost of plant material and sale price for powder increase 3% per year. MARKETING AND PRODUCT DEVELOPMENT ChyloCure will initially market its product as similar, but superior, to other CBD/CBDa rich powders. Over the past several months, we have produced product in small quantities for distribution at no charge to potential partners. These efforts have led to indications of interest from hemp-based cannabinoid retailers for purchase our product in kilogram quantities at prices equal to or in excess of those that we have used in our projections. We have also provided product for the past few months for three patients with severe epilepsy, both of whom have reported a dramatic decrease in the frequency and severity of their seizures. We intend to conduct a set of animal tests to demonstrate the superior absorption of our chylobinoids over CBD and CBDa. We believe that a demonstration of improved absorption will be sufficient to distinguish our product from others in the market place and intend to market the product based in substantial part on the results from those studies. We intend to rely on anecdotal evidence supplemented by later studies designed to support nutraceutical product claims to demonstrate effectiveness in the treatment of certain disease states. We believe that anecdotal evidence and absorption studies should allow us to price our product at a substantial premium to other CBD/CBDa rich powders. CAPITAL STRUCTURE Prior to the sale of the convertible notes, the Company will authorize 1,000,000 shares of common stock (300,000 shares of which will have been issued to Synthonics, Inc.) and 300,000 shares of preferred stock (none of which will have been issued). The common stock is valued at $10.00 per share giving the Company a pre-money valuation of $3.0 million. USE OF PROCEEDS We are seeking up to $1.0 million through this offer. Proceeds in that amount will be used to i) Pay initial licensing fee to Synthonics: $250,000 ii) Transaction costs $25,000 iii) Purchase rotovap and other equipment: $150,000 iv) Initial Build-Out $25,000 v) R&D expense (absorption and formulation studies): $100,000 vi) Operations $450,000 We reserve the right to close this offering with a smaller raise. In such case the payment of the initial licensing fee will be deferred in whole or in part to ensure that sufficient funds are on hand for initial operations.

5